Latest progress of docetaxel clinical pharmacokinetics

Mar 29
15:13

2012

David Yvon

David Yvon

  • Share this article on Facebook
  • Share this article on Twitter
  • Share this article on Linkedin

Docetaxel belongs to taxane anticancer drugs. It has an anti-tumor effect by inducing microtubule stability and destruction of the microtubule network dynamics. Docetaxel has shown a broad-spectrum anti-tumor activity in preclinical models and clinical treatment.

mediaimage

It is found in the reactions of many types of diseases,Latest progress of docetaxel clinical pharmacokinetics   Articles including advanced breast cancer and non-small cell lung cancer. Docetaxel pharmacokinetics and metabolism are very complex. In recent years, these scientists have been studied in the subject.

Docetaxel gets a range of metabolic transformation by cytochrome isoenzyme, resulting in formations of several pharmacological oxidation products without activity Docetaxel elimination of the route depends on the degree of presence of drug transporters, especially present in the bile tubule membrane glycoprotein. Adjust the drug elimination process, through metabolic breakdown or excretion of the ways to achieve. Docetaxel regimen of the individual strategy is based on ongoing cytochrome expression in the chia seed process is the difference of the phenotype or genotype may eventually make this drug a more selective chemotherapeutic use.

Anticancer drug docetaxel gets microtubule stabilization by aggregometry and inhibition of tubulin depolymerization, thereby undermining the dynamics of the microtubule network. Docetaxel’s variety treatments of active cancer include breast, lung, head and neck, ovarian and prostate cancer sites. It can be used to separate patients with locally advanced or metastatic breast cancer, and more soft than the star and cyclophosphamide used in conjunction with surgery, lymph node-positive breast cancer adjuvant therapy for the treatment of early failure of chemotherapy. It also can be used to treat a separate pre-failure of platinum-based chemotherapy for unresectable locally advanced or metastatic non-small cell lung cancer, in combination with cisplatin treatment did not receive pre-chemotherapy for unresectable locally advanced or metastatic non-small cell lung cancer and prednisone is used in conjunction with the treatment of androgen-dependent metastatic prostate cancer.

The dose of docetaxel for cancer treatment is 60mg/m2 to 100mg/m2 one hour in every three weeks. With this delivery method, most patients suffer from neutropenia syndrome. Occurrence rate of 75% degree of neutropenia disease and hot neutrophil reduce disease are 93% and 9% respectively. Dose of 100 mg/m2 in patients with metastatic breast cancer, the resveratrol occurrence probability is 65% and 6% respectively. Every three weeks regimen other adverse reactions include: alopecia, weakness, dermatology reaction, fluid stagnation, hypersensitivity, actuators and sensory neuropathy, stomatitis and diarrhea, and so on. Recently, there is a tendency around dropped to 25-40 mg/m2, docetaxel regimen to a weekly dose. Weekly dosing regimen is associated with the response rate this point and it is similar with every three weeks dosing regimen. But it can reduce bone marrow suppression reactions. However, such outcome has paid the price with increase of tears, skin nail toxicity and the negative impact on life quality.Source:http://www.cospcn.com